A retrospective study to determine efficacy and safety of olaparib/niraparib combined with pembrolizumab/nivolumab in patients with advanced tumors
Latest Information Update: 13 Oct 2021
At a glance
- Drugs Niraparib (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Pembrolizumab (Primary) ; Bevacizumab; Cisplatin; Etoposide; Oxaliplatin; Paclitaxel
- Indications Advanced breast cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Gynaecological cancer; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Rhabdomyosarcoma; Sarcoma; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 13 Oct 2021 New trial record
- 01 Oct 2021 Results published in the Cancer Immunology Immunotherapy